阿奇霉素治疗儿童哮喘控制不佳的随机对照试验
该开放标签随机对照试验纳入120例5-15岁哮喘控制不佳(ACT/CACT≤19)儿童,比较标准治疗联合阿奇霉素(10 mg/kg,每周三次,共3个月)与单用标准治疗。结果显示联合组3个月ACT/CACT评分更高,GINA良好控制比例更高,需急诊就诊和激素使用的急性加重次数更少,且FeNO、肺功能、咽拭子阳性及副作用无差异。
要点
- 阿奇霉素联合标准治疗可改善哮喘控制不佳儿童的ACT/CACT评分。
- 联合组GINA良好控制比例高于对照组(41/56 vs 10/56)。
- 阿奇霉素组需急诊和激素的急性加重次数更少。
核心结论
- 在哮喘控制不佳的儿童中,加用阿奇霉素可改善哮喘控制并减少急性加重。
研究设计与样本
- 开放标签随机对照试验,纳入120例5-15岁哮喘控制不佳(ACT/CACT≤19)儿童,每组60例。
主要发现
- 3个月时ACT/CACT评分阿奇霉素组为21.71±2.17,对照组为18.33±2.19(P<.001)。
- GINA良好控制比例阿奇霉素组41/56,对照组10/56(P<.001)。
- 需急诊就诊和激素使用的急性加重中位数阿奇霉素组0(IQR 3),对照组1(IQR 6)(P<.001)。
- FeNO水平、肺功能参数、咽拭子阳性结果及不良反应两组间无差异。
关键数值与推荐
- 阿奇霉素用法为10 mg/kg,每周三次,持续3个月,联合标准治疗。
- 哮喘控制不佳定义为ACT和CACT评分≤19。
临床怎么用
- 对于标准治疗下仍控制不佳的5-15岁哮喘儿童,可考虑加用阿奇霉素10 mg/kg每周三次共3个月以改善控制并减少急性加重。
局限性
- 开放标签设计可能引入偏倚。
- 样本量较小(120例),随访3个月,长期疗效与安全性未评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Azithromycin has immunomodulatory actions, and its beneficial effects have been demonstrated in asthmatic adults. Data on children are limited. RESEARCH QUESTION: Does the addition of oral azithromycin to standard therapy in children with poorly controlled asthma improve asthma control compared with standard treatment alone? STUDY DESIGN AND METHODS: This open-label randomized controlled trial included children (5-15 years of age) with poorly controlled asthma defined by Asthma Control Test (ACT) and Childhood Asthma Control Test (CACT) score of ≤ 19. They were randomized to receive azithromycin (10 mg/kg) three times weekly for 3 months along with standard treatment or standard treatment alone. The primary outcome was the ACT and CACT scores at 3 months. Secondary outcomes were asthma control according to Global Initiative for Asthma (GINA) guidelines, the number of exacerbations, change in spirometry parameters, change in fractional exhaled nitric oxide (Feno) level, positive throat swab results, and side effects. RESULTS: The trial included 120 children (89 boys; 60 in each group). The mean ± SD age was 9.9 ± 3 years. The baseline parameters were similar between the groups. Mean ± SD ACT and CACT scores (available for 115 children) at 3 months of intervention were 21.71 ± 2.17 vs 18.33 ± 2.19 (P < .001) in the azithromycin and control groups, respectively. The numbers of children with well-controlled asthma according to GINA guidelines were 41 of 56 vs 10 of 56 in the azithromycin and control groups, respectively (P < .001). The median number of exacerbations requiring emergency visit and steroid use were fewer in the azithromycin group: 0 (interquartile range [IQR], 3) vs 1 [IQR, 6]; P < .001). No difference was found in Feno level, spirometry parameters, positive throat swab results, and adverse effects between the groups. INTERPRETATION: The use of azithromycin in children with poorly controlled asthma resulted in improved asthma control and reduced exacerbations. TRIAL REGISTRY: Clinical Trials Registry - India; No.: CTRI/2019/06/019727; URL: www.ctri.nic.in.
引用
- Ghimire JJ, Jat KR, Sankar J, et al. Azithromycin for Poorly Controlled Asthma in Children: A Randomized Controlled Trial. Chest. 2022. PMID: 35202621. doi:10.1016/j.chest.2022.02.025
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。